MedTrace Logo

Continuous Infusion Terlipressin for Patients With Cirrhosis and Refractory Ascites

NCT03107091 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2021-07-13

Study results available
· View outcomes & findings →

Summary

Low-dose continuous infusion of terlipressin will be administered to six cirrhotic patients with refractory ascites.

Conditions

  • Cirrhosis
  • Ascites Hepatic

Interventions

DRUG

Terlipressin acetate continuous infusion

Low-dose continuous infusion of Terlipressin administered via ambulatory pump over 28 days

Sponsors & Collaborators

  • BioVie Inc.

    lead INDUSTRY

Principal Investigators

  • Patrick Yeramian, MD · BioVie Inc.

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-07-15
Primary Completion
2019-04-01
Completion
2019-04-25
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03107091 on ClinicalTrials.gov